About Us-CGeneTech_small molecular innovative drugs

About Us

Home page

About Shengshi Taikе

Shengshi Taike Biopharmaceutical Technology (Suzhou) Co., Ltd. is a biotechnology company in the commercial stage, and its core product, Class 1 innovative drug sengliptin (formerly known as Shenggliptin), has been approved for listing. The company was founded in Suzhou Industrial Park in 2010, and its core team has decades of experience in the entire life cycle of international drugs, committed to high-quality and differentiated innovative drug research and industrialization. The company has built a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases through an integrated drug research and development technology platform and diversified business perspectives,

the company has established a rich pipeline of innovative drugs covering hypoglycemic, anticancer, and autoimmune diseases In recent years, the DPP4 inhibitor, a new type of hypoglycemic drug, has become increasingly popular in China, and is praised by clinical doctors as the "smartest hypoglycemic drug". The new generation of highly selective DPP4 inhibitor Centagliptin independently developed by the company has been selected for the "Major New Drug Creation" special projects of the 12th and 13th Five Year Plans of the country. Currentlyapprovedforlisting. The results of the Phase 3 clinical trial showed that low doses can reach the predetermined trial endpoint, while the highdose group can also demonstrate excellent drug safety. The therapeutic effect of "half the dose, twice the effort" makes Centagliptin a promising candidate for bestnclass hypoglycemic drug. Additionally, the company has carried out a comprehensive layout of oral drugs and derivative diseases around the global mainstream targets of diabetes. Notably, the world's first SGLT2/DPP4 dualtarget inhibitor has been approved for clinical trials, aimed at better treating diabetes and its derivative diseases.

Among the anticancer drugs under development, four drugs have entered clinical trials. CGT-6321, a dual-target inhibitor of FGFR/VEGFR, has initiated phase I clinical trials in advanced solid tumors, with the potential to become a first-in-class drug. CGT-1967, a CDK4/6 inhibitor, is differentially selected for the treatment of acute myeloid leukemia (AML) patients, to explore the unmet clinical needs in this field. CXCR4 antagonists are receiving increasing attention globally, and CGT-1881, targeting this receptor, is used in hematopoietic stem cell mobilization and other therapeutic areas. According to third-party databases As the only original small-molecule oral CXCR4 antagonist in China, More convenient administration of medication; New generation ALK inhibitor CGT-9475, is expected to address several major clinical pain points in the treatment of lung cancer, including drug resistance and brain metastasis. Both the latter two projects have obtained clinical trial approval from the U.S. FDA, marking a solid step for the company's innovative drugs to enter the international market. Furthermore, the company's first domestically generic drug, teriflunomide tablets, for the treatment of the rare disease multiple sclerosis, is already on the market.

Looking ahead, the company will continue to focus on unmet clinical needs, developing innovative drugs with high accessibility and better efficacy to benefit patients worldwide.